Regulatory Landscape

How the FD&C Act, compounding law, and the FDA’s bulks-list process shape research-chemical access — including a real, current case study. Complete all 4 lessons and pass the quiz to earn your Regulatory Landscape certificate.

0%
0 of 4 lessons complete

Progress saves automatically in your browser.

Beginner

What “Research Use Only” Means Under the FD&C Act

Why that label exists, and the legal framework behind “not evaluated by the FDA” and “not for human or veterinary use.”

7 min

Beginner

Compounding and the 503A Bulks List

What compounding pharmacies are, and how FDA’s interim bulks-list categories (1, 2, and 3) work.

7 min

Beginner

A Real Case Study: The 2026 PCAC Peptide Review

What actually happened when FDA’s advisory committee reviewed BPC-157 and six other peptides for the 503A Bulks List.

8 min

Beginner

Why Regulatory Status Isn’t Permanent

Advisory recommendations vs. binding rulemaking, and why checking current status yourself matters.

6 min

← Back to Learn